Move OEG (Olfactory Ensheathing Glia) Transplants Into Human Clinical Trials for Spinal Cord Injury

Amidst all the controversy and promise surroundings stem cells there is a silent victory developing for spinal cord injury in labs in the United States and around the world. Unlike the newly discovered stem cell technology, a very special cell technology, OEG (olfactory ensheathing glia) is coming of age right now. OEG are a very versatile type of cell that has proven itself to be a very effective material for autologous transplantation and restoration of function in spinal cord injury. There is a wealth of scientific data on OEG to support this position. This technology is over 10 years in the making and those with spinal cord injury and their supporters want OEG to go into human clinical trials as soon as possible.. We the community of individuals with spinal cord injuries and their supporters would like to accomplish the following goals: First, greater public awareness of OEG and its indications for spinal cord injury in the media. The world should know about OEG. Second, increased and targeted institutional funding for human clinical trials of OEG transplants in spinal cord injury Third, increased and targeted government funding for human clinical trials of OEG transplants in spinal cord injury. And finally, those with expertise with OEG technology in the medical research community should take action now to move OEG transplants into human clinical trials We the undersigned believe, that it is in the best interest of the advancement of human progress and the compassionate interest of humanity to act upon the aforesaid goals and make human clinical trials of OEG transplants in spinal cord injury a reality.